Cargando…
Developing and user testing new pharmacy label formats—A study to inform labelling standards
BACKGROUND: Dispensed prescription medicine labels (prescription labels) are important information sources supporting safe and appropriate medicines use. OBJECTIVE: To develop and user test patient‐centred prescription label formats. METHODS: Five stages: developing 12 labels for four fictitious med...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369108/ https://www.ncbi.nlm.nih.gov/pubmed/34076940 http://dx.doi.org/10.1111/hex.13203 |
_version_ | 1783739221169668096 |
---|---|
author | Tong, Vivien Aslani, Parisa Raynor, David K. Shipp, Diana Parkinson, Brian Lalor, Daniel Sobey, Andrew Gilbert, Alice Crofton, Jackie Young, Joanne Carter, Sophie Poon, Wing Chitlangia, Shrada |
author_facet | Tong, Vivien Aslani, Parisa Raynor, David K. Shipp, Diana Parkinson, Brian Lalor, Daniel Sobey, Andrew Gilbert, Alice Crofton, Jackie Young, Joanne Carter, Sophie Poon, Wing Chitlangia, Shrada |
author_sort | Tong, Vivien |
collection | PubMed |
description | BACKGROUND: Dispensed prescription medicine labels (prescription labels) are important information sources supporting safe and appropriate medicines use. OBJECTIVE: To develop and user test patient‐centred prescription label formats. METHODS: Five stages: developing 12 labels for four fictitious medicines of varying dosage forms; diagnostic user testing of labels (Round 1) with 40 consumers (each testing three labels); iterative label revision, and development of Round 2 labels (n = 7); user testing of labels (Round 2) with 20 consumers (each testing four labels); labelling recommendations. Evaluated labels stated the active ingredient and brand name, using various design features (eg upper case and bold). Dosing was expressed differently across labels: frequency of doses/day, approximate times of day (eg morning), explicit times (eg 7 to 9 AM), and/or explicit dosing interval. Participants’ ability to find and understand medicines information and plan a dosing schedule were assessed. RESULTS: Participants demonstrated satisfactory ability to find and understand the dosage for all label formats. Excluding active ingredient and dosing schedule, 14/19 labels (8/12 in Round 1; 6/7 in Round 2) met industry standard on performance. Participants’ ability to correctly identify the active ingredient varied, with clear medicine name sign‐posting enabling all participants evaluating these labels to find and understand the active ingredient. When planning a dosing schedule, doses were correctly spaced if the label stated a dosing interval, or frequency of doses/day. Two‐thirds planned appropriate dosing schedules using a dosing table. CONCLUSIONS: Effective prescription label formatting and sign‐posting of active ingredient improved communication of information on labels, potentially supporting safe medicines use. PATIENT AND PUBLIC INVOLVEMENT: Consumers actively contributed to the development of dispensed prescription medicine labels. Feedback from consumers following the first round was incorporated in revisions of the labels for the next round. Patient and public involvement in this study was critical to the development of readable and understandable dispensed prescription medicine labels. |
format | Online Article Text |
id | pubmed-8369108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83691082021-08-23 Developing and user testing new pharmacy label formats—A study to inform labelling standards Tong, Vivien Aslani, Parisa Raynor, David K. Shipp, Diana Parkinson, Brian Lalor, Daniel Sobey, Andrew Gilbert, Alice Crofton, Jackie Young, Joanne Carter, Sophie Poon, Wing Chitlangia, Shrada Health Expect Original Articles BACKGROUND: Dispensed prescription medicine labels (prescription labels) are important information sources supporting safe and appropriate medicines use. OBJECTIVE: To develop and user test patient‐centred prescription label formats. METHODS: Five stages: developing 12 labels for four fictitious medicines of varying dosage forms; diagnostic user testing of labels (Round 1) with 40 consumers (each testing three labels); iterative label revision, and development of Round 2 labels (n = 7); user testing of labels (Round 2) with 20 consumers (each testing four labels); labelling recommendations. Evaluated labels stated the active ingredient and brand name, using various design features (eg upper case and bold). Dosing was expressed differently across labels: frequency of doses/day, approximate times of day (eg morning), explicit times (eg 7 to 9 AM), and/or explicit dosing interval. Participants’ ability to find and understand medicines information and plan a dosing schedule were assessed. RESULTS: Participants demonstrated satisfactory ability to find and understand the dosage for all label formats. Excluding active ingredient and dosing schedule, 14/19 labels (8/12 in Round 1; 6/7 in Round 2) met industry standard on performance. Participants’ ability to correctly identify the active ingredient varied, with clear medicine name sign‐posting enabling all participants evaluating these labels to find and understand the active ingredient. When planning a dosing schedule, doses were correctly spaced if the label stated a dosing interval, or frequency of doses/day. Two‐thirds planned appropriate dosing schedules using a dosing table. CONCLUSIONS: Effective prescription label formatting and sign‐posting of active ingredient improved communication of information on labels, potentially supporting safe medicines use. PATIENT AND PUBLIC INVOLVEMENT: Consumers actively contributed to the development of dispensed prescription medicine labels. Feedback from consumers following the first round was incorporated in revisions of the labels for the next round. Patient and public involvement in this study was critical to the development of readable and understandable dispensed prescription medicine labels. John Wiley and Sons Inc. 2021-06-02 2021-08 /pmc/articles/PMC8369108/ /pubmed/34076940 http://dx.doi.org/10.1111/hex.13203 Text en © 2021 The Authors. Health Expectations published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Tong, Vivien Aslani, Parisa Raynor, David K. Shipp, Diana Parkinson, Brian Lalor, Daniel Sobey, Andrew Gilbert, Alice Crofton, Jackie Young, Joanne Carter, Sophie Poon, Wing Chitlangia, Shrada Developing and user testing new pharmacy label formats—A study to inform labelling standards |
title | Developing and user testing new pharmacy label formats—A study to inform labelling standards |
title_full | Developing and user testing new pharmacy label formats—A study to inform labelling standards |
title_fullStr | Developing and user testing new pharmacy label formats—A study to inform labelling standards |
title_full_unstemmed | Developing and user testing new pharmacy label formats—A study to inform labelling standards |
title_short | Developing and user testing new pharmacy label formats—A study to inform labelling standards |
title_sort | developing and user testing new pharmacy label formats—a study to inform labelling standards |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369108/ https://www.ncbi.nlm.nih.gov/pubmed/34076940 http://dx.doi.org/10.1111/hex.13203 |
work_keys_str_mv | AT tongvivien developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT aslaniparisa developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT raynordavidk developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT shippdiana developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT parkinsonbrian developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT lalordaniel developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT sobeyandrew developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT gilbertalice developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT croftonjackie developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT youngjoanne developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT cartersophie developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT poonwing developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards AT chitlangiashrada developingandusertestingnewpharmacylabelformatsastudytoinformlabellingstandards |